These companies are carving their own paths in cellular medicine. One just posted promising clinical results, while the other aims to do so this month.
Forty Seven jumped on promising data for its lead drug candidate.
These industry leaders aren't getting much love from Mr. Market. That just sets the stage for an inevitable rebound, right?
These two companies are piggybacking on the growth of solar energy and distributed energy generation.
Global emissions reduction efforts are likely to be much more successful if one controversial energy source is included -- if only temporarily.
An amended collaboration agreement limited the types of immune cells that will be pursued by the duo, but that could create more value for Editas Medicine in the long run.
An important clinical trial turned in underwhelming results.
Now that the initial excitement has worn off, investors are correctly responding to the news of a public stock offering.
The business reported a handful of positive developments.
The rare-disease specialist is putting together a respectable end-of-year run.
The gene editing pioneer got a boost from a collaborator and a competitor.
The diagnostic company reported third-quarter 2019 operating results.
Counterintuitively, investors are bidding up the share price after the company announced a public stock offering.
The RNAi pioneer earned a surprise drug approval. It could have far-reaching implications for the company's future.
The gene-editing pioneer reported promising data, albeit from two patients.
The stock price is soaring. Are investors getting ahead of themselves by speculating on a potential acquisition?
Investors were caught off guard when the genetic medicines company earned marketing approval for its second RNAi drug product sooner than expected.
The latest progress report on global emissions reduction efforts showed there's a lot room for improvement, but the United States is doing its part.
The FDA rebuffed the company's appeal for a failed new drug application. What happens now?
Despite doubts over its lead drug candidate and the loss of a major partner, the company is forging ahead.